Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening
infectious complications following allogeneic hematopoietic stem cell transplantation …

Human cytomegalovirus (CMV) is a betaherpesvirus in the same family as human
herpesvirus-6 and-7. CMV is a large virus including approximately 200 proteins. CMV has …

Abstract The Practice Guidelines Committee of the American Society for Transplantation and
Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to …

Cytomegalovirus (CMV) is recognized as the most common congenital viral infection in
humans and an important cause of morbidity and mortality in immunocompromised hosts …

We adoptively transferred donor-derived cytomegalovirus (CMV)-specific T-cell lines into 8
stem cell transplant recipients lacking CMV-specific T-cell proliferation. All patients, of whom …

After initial infection, human cytomegalovirus remains in a persistent state with the host.
Immunity against the virus controls replication, although intermitent viral shedding can still …

Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT)
remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases …

Background Available drugs against cytomegalovirus have adverse effects that compromise
their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the …

Ganciclovir effectively prevents cytomegalovirus (CMV) disease in the first 100 days after
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …

This article contains highlights of “Guidelines for Preventing Opportunistic Infections among
Hematopoietic Stem Cell Transplant Recipients: Recommendations of the CDC, the …